Subscribe to RSS
DOI: 10.1055/s-0043-121771
Personalisierte Tumortherapie bei metastasierten gastrointestinalen Tumoren
Aktueller Stand und Einordnung in den klinischen KontextPublication History
Publication Date:
15 November 2017 (online)
![](https://www.thieme-connect.de/media/klinikarzt/201711/lookinside/thumbnails/10-1055-s-0043-121771-1.jpg)
Zusammenfassung
Personalisierte Therapiestrategien haben sich in den letzten Jahren auch in der gastrointestinalen Onkologie etabliert. Personalisierte Therapiestrategien umfassen Substanzen, die gezielt am Tumor angreifen, sog. „targeted therapies“. Zunehmende Bedeutung als Targets gewinnen das Microenvironment des Tumors und das Immunsystem. Parallel zu den neuen Substanzen werden Biomarker identifiziert, die den Einsatz einer bestimmten Substanz sinnvoll erscheinen lassen oder ausschließen. Dies ist nicht nur vorteilhaft für Patienten, die so Therapien mit hoher Aussicht auf Wirksamkeit erhalten, sondern auch für das Gesundheitswesen, dem Kosten für nicht wirksame Therapien erspart bleiben. Diese Übersicht soll den aktuellen Stand von personalisierten Therapiestrategien bei kolorektalen, Pankreas- und Magenkarzinomen darstellen und in den klinischen Kontext einordnen.
-
Literatur
- 1 Guinney J, Dienstmann R, Wang X. et al. The consencus molecular subtypes of colorectal cancer. Nat Med 2015; 21: 1350-1356
- 2 Graham DM, Coyle VM, Kennedy RD. et al. Molecular subtypes and personalized therapy in metastatic colorectal cancer. Curr Colorectal Cancer Rep 2016; 12: 141-150
- 3 Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-209
- 4 Bailey P, Chang DK, Nones K. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016; 531: 47-52
- 5 Heinemann V, von Weikersthal LF, Decker T. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065-1075
- 6 Wilke H, Muro K, Van Cutsem E. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet 2014; Lancet Oncol 15: 1224-1235
- 7 Vidal J, Muinelo L, Dalmases A. et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol 2017; 28: 1325-1332
- 8 Di Nicolantonio F, Martini M, Molinari F. et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712
- 9 Jones JC, Renfro LA, Al-Shamsi HO. et al. Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. J Clin Oncol 2017; 35: 2624-2630
- 10 Cremolini C, Loupakis F, Antoniotti C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306-1315
- 11 Sortore-Bianchi A, Trusolino L, Martino C. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatmet-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17: 738-746
- 12 Douillard JY, Oliner KS, Siena S. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034
- 13 Schwartzberg LS, Rivera F, Karthaus M. et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014; 32: 2240-2247
- 14 Stinzing S, Miller-Phillips L, Modest DP. et al. FIRE-3 Investigators. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. Eur J Cancer 2017; 79: 50-60
- 15 Lenz H, Niedzwiecki D, Innocenti F. et al. CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC). Ann Onc 2014; 5: 1-41
- 16 Van Cutsem E, Lenz HJ, Köhne CH. et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015; 33: 692-700
- 17 Holch JW, Ricard I, Stintzing S. et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Eur J Cancer 2017; 70: 87-98
- 18 Misale S, Yaeger R, Hobor S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-536
- 19 Corcoran RB, Ebi H, Turke AB. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2: 227-235
- 20 Kopetz S, Desai J, Chan E. et al. Phase II Pilot Study of Vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 2015; 33: 4032-4038
- 21 Bang YJ, Van Cutsem E, Feyereislova A. et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697
- 22 Tabernero J, Hoff PM, Shen L. Pertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): final analysis of a phase III study (JACOB). Presented at: European Society for Medical Oncology (ESMO) 2017 Congress; September 8–12 2017. Madrid, Spain:
- 23 Saltz LB, Clarke S, Diaz-Rubio E. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019
- 24 Giantonio BJ, Catalano PJ, Meropol NJ. et al. Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544
- 25 Bennouna J, Sastre J, Arnold D. et al. ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37
- 26 Tabernero J, Van Cutsem E, Lakomy R. et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 2014; 50: 320-331
- 27 Kabbinavar F, Hurwitz HI, Fehrenbacher L. et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65
- 28 Cunningham D, Lang I, Marcuello E. et al. AVES study investigators. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14: 1077-1085
- 29 Simkens LH, van Tinteren H, May A. et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015; 385: 1843-1852
- 30 Arnold D, Graeven U, Lerchenmuller CA. et al. Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207). J Clin Oncol 2014; 32 5 s (suppl; abstr 3503)
- 31 Vogelstein B, Fearon ER, Hamilton SR. et al. Genetic alterations during colorectal tumor development. N Engl J Med 1988; 319: 525-532
- 32 Fuchs CS, Tomasek J, Yong CJ. et al. REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39
- 33 Özdemir BC, Pentcheva-Hoang T, Carstens JL. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014; 25: 719-734
- 34 Rhim AD, Oberstein PE, Thomas DH. et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014; 25: 735-747
- 35 Hingorani SR, Harris WP, Hendifar AE. et al. High response rate an PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized phase II study. J Clin Oncol 2015; 33 (suppl; abstr 4006)
- 36 Le DT, Uram JN, Wang H. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372: 2509-2510
- 37 Fuchs CS, Doi T, Jang RWJ. et al. KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. J Clin Oncol 2017; 35 (suppl; abstr 4003)
- 38 Janjigian YY, Ott PA, Calvo E. et al. Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. J Clin Oncol 2017; 35 (suppl; abstr 4014)
- 39 Boku N, Kang YK, Sato T. et al. A phase 3 study of nivolumab (nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02). Ann Oncol 2017; 28 (suppl_5; Abstr 617O)